Who won big at #AACR18? Merck surges on Keytruda/chemo combo while Bristol-Myers shares tumble on comparison
Merck and Bristol-Myers Squibb both came to AACR looking to score points in their long-running slugfest over the lung cancer market. Both had promising results, but Merck’s KEYNOTE-189 was clearly the big winner this morning.
Merck shares $MRK gained close to 3% on its case that a combination of Keytruda with chemo offered solid, across-the-board benefits for a large segment of frontline cases, which will go a long way to winning over physicians and patents with its 0.49 hazard ration.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters